MedTrace Logo

Comparative Single-dose Bioavailability Clinical Study of Different Coenzyme Q10 Products

NCT05272228 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-07-21

No results posted yet for this study

Summary

The randomized, open-label, three period crossover single-dose bioavailability study with three coenzyme Q10 products

Conditions

  • Coenzyme Q Deficiency

Interventions

DIETARY_SUPPLEMENT

Dietary supplement - standard product

Single dose intervention with Standard product Coenzyme Q10 (ubiquinone) 2 capsules - 100 mg total coenzyme Q10

DIETARY_SUPPLEMENT

Dietary supplement - Investigational product IP1

Single dose intervention with Investigational product IP1; Q10 MICROENCAPSULATED 2 capsules - 100 mg total coenzyme Q10

DIETARY_SUPPLEMENT

Dietary supplement - Investigational product IP2

Single dose intervention with Investigational product IP2; Final formulated product BQSM® 2 capsules - 100 mg total coenzyme Q10

Sponsors & Collaborators

  • Biovis d.o.o.

    collaborator UNKNOWN

  • University of Primorska

    lead OTHER

Principal Investigators

  • Zala Jenko-Pražnikar, PhD · University of Primorska, Faculty of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-09
Primary Completion
2022-05-15
Completion
2022-07-15

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272228 on ClinicalTrials.gov